-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Wind data shows that as of the evening of April 6, 25 pharmaceutical companies have disclosed first-quarter performance forecasts, and more than 80% of the companies are pre-happy
.
From the perspective of net profit growth, the net profit of the six companies increased by more than 100% year-on-year, mainly in the fields of testing and biological products
.
Among them, the testing company Aotai Biological has outstanding performance.
In the first quarter, thanks to the company's continuous stable growth in testing business orders, it is expected to achieve a net profit attributable to owners of the parent company of 1.
03 billion to 1.
19 billion yuan, a year-on-year increase of 585.
40% to 691.
87 %
.
The first quarter of companies in the field of biological products was also remarkable
.
For example, Tonghua Dongbao, an "insulin leader", expects to achieve a net profit of 817 million yuan attributable to shareholders of listed companies in the first quarter of 2022, an increase of 480 million yuan over the same period last year, or an increase of about 142.
63% over the same period last year
.
It is reported that during the reporting period, the revenue scale of Tonghua Dongbao continued to grow
.
At the same time, according to the needs of business development, in order to concentrate on accelerating the transformation into an innovative pharmaceutical enterprise, lay a solid foundation for the medium and long-term development of the enterprise, and safeguard the interests of all shareholders of the listed company, the company sold part of the shares of Xiamen Tebao Bioengineering Co.
, Ltd.
, and the investment income increase
.
The company stated that, thanks to the larger-scale effect brought about by revenue growth, the reduction of procurement costs, the increase in the proportion of high-margin products, the improvement of operational efficiency, and the control of sales expenses, the company's gross profit margin in the first quarter of 2021.
It reached 83.
2% and the net profit rate reached 40.
9%, which undoubtedly gave investors a boost
.
Another example is the domestic vaccine giant Zhifei Bio.
The company announced on the evening of March 30 that it expects a net profit of 1.
782 billion yuan to 1.
97 billion yuan in the first quarter of 2022, a year-on-year increase of 90%-110%
.
Regarding the reasons for the increase in net profit, Zhifei Bio said that during the reporting period, the company steadily promoted product research and development, production, promotion, sales and other work around the annual business goals and plans
.
The company always attaches great importance to the production and sales promotion of its own products, and continues to increase the purchase of agency products to ensure the supply of various products to meet the national disease prevention needs
.
During the reporting period, the number of batches issued by the company's main products for sale has increased significantly, and the marketing team has actively carried out various promotion services and achieved good results
.
The company's main business income, net profit and other important financial indicators have increased significantly compared with the same period of the previous year
.
It is worth mentioning that although the overall performance of biological product companies is good, the stock price trends of some pharmaceutical companies are not synchronized
.
For example, Tonghua Dongbao, since the stock hit a new high of 27.
11 yuan in May 2018, the stock price has begun to go down and has been stagnant for many years
.
On March 9, 2022, Tonghua Dongbao hit a new low of 9.
25 yuan per share during the year
.
As of the close on March 9, Tonghua Dongbao reported 9.
56 yuan per share, with a total market value of 19.
21 billion yuan
.
In order to maintain the company's market image and enhance investor confidence, on the evening of March 9, Tonghua Dongbao announced that the company decided to use its own funds to repurchase the company's shares, and the number of repurchases should not be less than 12 million shares (inclusive).
More than 24 million shares (inclusive), accounting for 0.
6% and 1.
19% of the company's total share capital
.
The repurchase price does not exceed 15 yuan per share (inclusive), and the total amount of funds to be repurchased is capped at 360 million yuan (inclusive)
.
However, from the perspective of the industry, Tonghua Dongbao's performance in the first quarter of this year exceeded expectations and may return to growth
.
In the sixth batch of special centralized procurement of insulin, Tonghua Dongbao performed more prominently.
The company's entire series of insulin products successfully won the bid for category B, and a total of 5 products were to be selected, including full-standard human insulin injection, insulin glargine injection and Insulin aspart injection
.
The company recently stated on the interactive platform that in the first quarter of this year, the company's second-generation insulin sales were good, insulin glargine continued to increase, and insulin aspart admissions accelerated
.
The company has full confidence in the long-term development in the future
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
From the perspective of net profit growth, the net profit of the six companies increased by more than 100% year-on-year, mainly in the fields of testing and biological products
.
Among them, the testing company Aotai Biological has outstanding performance.
In the first quarter, thanks to the company's continuous stable growth in testing business orders, it is expected to achieve a net profit attributable to owners of the parent company of 1.
03 billion to 1.
19 billion yuan, a year-on-year increase of 585.
40% to 691.
87 %
.
The first quarter of companies in the field of biological products was also remarkable
.
For example, Tonghua Dongbao, an "insulin leader", expects to achieve a net profit of 817 million yuan attributable to shareholders of listed companies in the first quarter of 2022, an increase of 480 million yuan over the same period last year, or an increase of about 142.
63% over the same period last year
.
It is reported that during the reporting period, the revenue scale of Tonghua Dongbao continued to grow
.
At the same time, according to the needs of business development, in order to concentrate on accelerating the transformation into an innovative pharmaceutical enterprise, lay a solid foundation for the medium and long-term development of the enterprise, and safeguard the interests of all shareholders of the listed company, the company sold part of the shares of Xiamen Tebao Bioengineering Co.
, Ltd.
, and the investment income increase
.
The company stated that, thanks to the larger-scale effect brought about by revenue growth, the reduction of procurement costs, the increase in the proportion of high-margin products, the improvement of operational efficiency, and the control of sales expenses, the company's gross profit margin in the first quarter of 2021.
It reached 83.
2% and the net profit rate reached 40.
9%, which undoubtedly gave investors a boost
.
Another example is the domestic vaccine giant Zhifei Bio.
The company announced on the evening of March 30 that it expects a net profit of 1.
782 billion yuan to 1.
97 billion yuan in the first quarter of 2022, a year-on-year increase of 90%-110%
.
Regarding the reasons for the increase in net profit, Zhifei Bio said that during the reporting period, the company steadily promoted product research and development, production, promotion, sales and other work around the annual business goals and plans
.
The company always attaches great importance to the production and sales promotion of its own products, and continues to increase the purchase of agency products to ensure the supply of various products to meet the national disease prevention needs
.
During the reporting period, the number of batches issued by the company's main products for sale has increased significantly, and the marketing team has actively carried out various promotion services and achieved good results
.
The company's main business income, net profit and other important financial indicators have increased significantly compared with the same period of the previous year
.
It is worth mentioning that although the overall performance of biological product companies is good, the stock price trends of some pharmaceutical companies are not synchronized
.
For example, Tonghua Dongbao, since the stock hit a new high of 27.
11 yuan in May 2018, the stock price has begun to go down and has been stagnant for many years
.
On March 9, 2022, Tonghua Dongbao hit a new low of 9.
25 yuan per share during the year
.
As of the close on March 9, Tonghua Dongbao reported 9.
56 yuan per share, with a total market value of 19.
21 billion yuan
.
In order to maintain the company's market image and enhance investor confidence, on the evening of March 9, Tonghua Dongbao announced that the company decided to use its own funds to repurchase the company's shares, and the number of repurchases should not be less than 12 million shares (inclusive).
More than 24 million shares (inclusive), accounting for 0.
6% and 1.
19% of the company's total share capital
.
The repurchase price does not exceed 15 yuan per share (inclusive), and the total amount of funds to be repurchased is capped at 360 million yuan (inclusive)
.
However, from the perspective of the industry, Tonghua Dongbao's performance in the first quarter of this year exceeded expectations and may return to growth
.
In the sixth batch of special centralized procurement of insulin, Tonghua Dongbao performed more prominently.
The company's entire series of insulin products successfully won the bid for category B, and a total of 5 products were to be selected, including full-standard human insulin injection, insulin glargine injection and Insulin aspart injection
.
The company recently stated on the interactive platform that in the first quarter of this year, the company's second-generation insulin sales were good, insulin glargine continued to increase, and insulin aspart admissions accelerated
.
The company has full confidence in the long-term development in the future
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
